Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control (Aspylori)
Comparative Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control on the Gastric Lesions Induced by the Aspirin With the Low Dose Among Patients Treated With the Long Course
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75181
- Hotel Dieu Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients of more than 18 years old
- Coronarography or coronary imaging or supra-aortic arterial trunks ultrasound examination performed since less 7 months and having at least an arterial vascular stenosis
- Indication for aspirin treatment for at least 12 months (at the moment of the visit of inclusion) at a posology from 80 to 125 mg per day. The treatment must be prescribed since less than 7 months.
- Patient who had since less 7 month a positive Helicobacter Pylori serology.
- For the women in age to procreate, effective mode of contraception (oral contraception, surgical sterilization, coil)
- Patient having given an informed consent according to recommendation of the CPP (institutional ethical committee).
Exclusion Criteria:
- treatment by anti-coagulant, whatever its nature and its posology, by proton pump inhibitor, H2 receptor antagonists or antiacid having to be continued beyond the day of inclusion
- Treatment by methotrexate in progress or stopped since less 3 months.
- Time of more 7 months enters the beginning of the treatment by aspirin and the visit of inclusion
- Treatment by NSAID (even occasional or self medication) under or stopped since less 3 months.
- Treatment by anti-platelet drug (clopidogrel, ticlopidine, flurbiprofen, dipyridamole or antagonist of receptor GPIIb/IIIa) in progress or stopped since less than 10 days.
- Patient with a serious pathology compromising survival in the 6 month to come.
- Patient with renal or respiratory insufficiency or a hepatic pathology having a clinical repercussion.
- History of surgery of esophagus, stomach or duodenum.
- History of digestive tract bleeding or gastro-duodenal ulcer or esophagal ulcerating proven by endoscopy.
- Allergy known to clarithromycin.
- Psychiatric disorder not controlled by treatment.
- Patients all ready include in a therapeutic protocol or to be followed for 6 month.
- Alcohol consumption higher than 100gr. per day.
- Patient non suitable for participating in the protocol or to be followed for 6 month.
- History of intolerance to salicylate.
- Constitutional or acquired hemorrhagic disease
- Pregnant woman or nursing.
- Patient in emergency, people hospitalized without their assent, people without freedom, people without social health insurance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: C
Placebo
|
26 weeks, one tablet per day
|
|
Active Comparator: A
Amoxicillin, Clarythromycin or metronidazole,Pantoprazole,Placebo
|
during one week for the active treatments placebo during 25 weeks
Other Names:
|
|
Experimental: B
Pantoprazole
|
6 months at 20 mg
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Measure: severity of the ulcerated gastric lesions induced by the aspirin
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To measure: percentage of patients having had at least an ulcer
Time Frame: 6 months
|
6 months
|
|
To measure: the average of the ranks of lesion in antrum and corpus.
Time Frame: 6 months
|
6 months
|
|
To measure percentage of patients having had digestive clinical events
Time Frame: 6 months
|
6 months
|
|
To measure: the average of the ranks of severity of the hemorrhagic lesions and erosive lesions evaluated in antrum and corpus by two analogical scales of 150 mm
Time Frame: 6 months
|
6 months
|
|
To measure Percentage of patients having a hemorrhagic digestive of clinical expression or detected by the biological tests.
Time Frame: 6 months
|
6 months
|
|
To measure : Elements of the histopathologic score of Sydney
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dominique Lamarque, MD, PhD, Assistance Publique Hopitaux De Paris
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Heart Diseases
- Embolism and Thrombosis
- Coronary Disease
- Myocardial Ischemia
- Thrombosis
- Coronary Thrombosis
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Sulfoxides
- Sulfur Compounds
- Organic Chemicals
- Pyridines
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Benzimidazoles
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Azoles
- Imidazoles
- Amides
- Penicillin G
- beta-Lactams
- Lactams
- Nitroimidazoles
- Nitro Compounds
- Ampicillin
- Penicillins
- Pantoprazole
- Metronidazole
- Amoxicillin
Other Study ID Numbers
Other Study ID Numbers
- P051021
- AOM 05114
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.